List of Excipients in Branded Drug JORNAY PM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Ironshore Pharmaceuticals Inc	JORNAY PM	methylphenidate hydrochloride	71376-201	CELLULOSE, MICROCRYSTALLINE
Ironshore Pharmaceuticals Inc	JORNAY PM	methylphenidate hydrochloride	71376-201	DIBUTYL SEBACATE
Ironshore Pharmaceuticals Inc	JORNAY PM	methylphenidate hydrochloride	71376-201	ETHYLCELLULOSE

JORNAY PM Excipient Strategy and Commercial Opportunities

Last updated: October 11, 2026

JORNAY PM is a once-daily, evening-dosed methylphenidate hydrochloride product for ADHD in patients age 6 years and older. Its commercial differentiation depends on multiparticulate bead engineering rather than on a novel active ingredient. The formulation uses separate delayed-release and extended-release functions to suppress overnight drug release and deliver methylphenidate during the following day. That architecture creates opportunities for excipient suppliers, generic manufacturers, lifecycle developers, and competing long-acting ADHD products.

What excipients are used in JORNAY PM?

JORNAY PM uses coated multiparticulate beads contained in hard gelatin capsules. The inactive ingredients identified in FDA labeling include sugar spheres, hypromellose, povidone, talc, ethylcellulose, triethyl citrate, gelatin, titanium dioxide, and capsule colorants.[1]

Formulation component	Likely technical role
Sugar spheres	Inert bead cores for drug layering
Povidone	Binder for applying methylphenidate to the bead cores
Hypromellose	Film-forming polymer and release-control component
Ethylcellulose	Water-insoluble diffusion barrier for extended release
Talc	Anti-tacking and coating-process aid
Triethyl citrate	Plasticizer that improves coating flexibility
Gelatin	Hard capsule shell
Titanium dioxide and colorants	Capsule opacity and product identification

The label identifies inactive ingredients, but it does not disclose the complete manufacturing process, coating weight gains, polymer ratios, particle-size distribution, drug-layer thickness, or dissolution specifications. Those variables are central to reproducing JORNAY PM's in vitro and in vivo release profile.

How does the JORNAY PM release mechanism work?

JORNAY PM uses two release controls. The outer barrier delays release until after administration, while the inner coating extends methylphenidate release after the delay period.[1]

The formulation is designed to provide:

1. Minimal drug release during the night.
2. Delayed onset after gastrointestinal transit.
3. Extended daytime exposure following evening administration.
4. A dosing schedule that avoids morning administration.

The delayed-release function is commercially important because it allows evening dosing without producing the principal stimulant exposure overnight. The extended-release function then supports symptom control during the school or work day.

This combination differs from standard extended-release methylphenidate products that are administered in the morning. The commercial value is therefore linked to timing of exposure, not only to total daily dose.

Which excipients create the main technical barriers?

Ethylcellulose and hypromellose coating systems

Ethylcellulose is commonly used as a water-insoluble membrane for diffusion-controlled release. Hypromellose can provide film formation, improve mechanical integrity, and modify water penetration. Their ratio, viscosity grade, concentration, and coating weight can materially affect dissolution.

Small process changes can alter:

• Lag time.
• Release rate after the lag period.
• Dose dumping risk.
• Batch-to-batch reproducibility.
• Sensitivity to gastrointestinal pH and transit conditions.

A generic manufacturer cannot rely on the same nominal excipient list alone. It must reproduce the drug-release behavior and demonstrate bioequivalence under the applicable FDA pathway.

Triethyl citrate

Triethyl citrate acts as a plasticizer for polymer films. It can reduce brittleness and improve coating durability. Its concentration affects film permeability and mechanical properties. Excessive plasticization may increase release, while inadequate plasticization can create cracking or coating defects.

Triethyl citrate is widely available and is unlikely to provide strong standalone exclusivity. Its commercial importance lies in the optimized coating system and manufacturing controls.

Sugar spheres

Sugar spheres support drug layering and multiparticulate processing. Their particle-size distribution affects surface area, drug-loading uniformity, coating thickness, capsule fill weight, and dissolution.

Supplier qualification is important because variations in:

• Particle size.
• Density.
• Moisture.
• Surface morphology.
• Mechanical strength.

can affect the finished product. A second-source strategy may require process requalification and comparative dissolution testing.

Povidone

Povidone functions as a binder during drug layering. Molecular weight, solution concentration, solvent system, and spray conditions can affect methylphenidate adhesion and content uniformity. Povidone is a commodity excipient, but the process window for uniform drug deposition may be product-specific.

What formulations are protected by JORNAY PM's commercial design?

The key formulation value is the combination of:

• Methylphenidate hydrochloride.
• Multiparticulate bead construction.
• Delayed release after evening administration.
• Extended release during the following day.
• Capsule delivery with the ability to open the capsule and sprinkle contents on applesauce without chewing, according to labeling.[1]

The commercial protection is more likely to reside in the overall dosage-form architecture, release profile, method of administration, and manufacturing controls than in the presence of any individual excipient. Sugar spheres, hypromellose, ethylcellulose, povidone, talc, and triethyl citrate are established pharmaceutical materials with broad prior use.

The strongest product-specific barriers are likely to include:

• The precise delayed-release and extended-release combination.
• Dissolution behavior across multiple pH conditions.
• Coating sequence and coating thickness.
• Multiparticulate dose uniformity.
• Stability of coated beads.
• The relationship between in vitro release and in vivo exposure.

What is the FDA regulatory status of JORNAY PM?

JORNAY PM was approved by the FDA in August 2018 under NDA 211206 for ADHD in patients 6 years and older.[1] It is a controlled substance containing methylphenidate, a Schedule II stimulant in the United States.

The product is subject to the regulatory requirements applicable to controlled-release methylphenidate products, including:

• Controlled-substance manufacturing and distribution controls.
• Abuse, misuse, and addiction warnings.
• Pediatric safety monitoring.
• Bioequivalence requirements for abbreviated applications.
• Labeling restrictions related to capsule opening and administration.

The product's approval is based on the finished dosage form and its clinical and pharmacokinetic profile. Excipients used in a follow-on product must be justified for safety, quality, performance, and compatibility.

What is the Orange Book status of JORNAY PM?

JORNAY PM is listed in the FDA Orange Book under its approved NDA. The relevant regulatory question for a generic applicant is whether current patent and exclusivity listings block an ANDA filing, require a Paragraph IV certification, or permit a filing with a later launch date.[2]

For this product, an ANDA applicant would need to evaluate:

• Listed drug identity and dosage strengths.
• Current patent listings.
• Expiration dates and pediatric extensions.
• Exclusivity entries.
• Whether patents claim the formulation, method of use, or both.
• Whether a Paragraph IV certification would trigger Hatch-Waxman litigation.

Patent and exclusivity status can change through correction, delisting, litigation, settlement, pediatric extensions, or regulatory updates. A commercial diligence report must use the current Orange Book record rather than relying on historical patent summaries.

When does JORNAY PM lose exclusivity?

The active ingredient, methylphenidate hydrochloride, is long established and is not the principal source of current product exclusivity. The timing of generic entry depends on product-specific patents, regulatory exclusivity, litigation outcomes, and any settlement terms.

A generic launch may occur through several pathways:

Scenario	Commercial effect
Patent expiration without litigation	Entry may begin when FDA approval and other conditions are satisfied
Paragraph IV filing followed by litigation	Launch may be delayed by the 30-month stay or court action
Settlement with a licensed entry date	Entry occurs on the agreed date, subject to settlement terms
Patent invalidation or non-infringement ruling	Earlier launch may become possible
Authorized generic or licensed generic	Competition may enter without a conventional independent ANDA launch
505(b)(2) lifecycle product	A differentiated dosage form may avoid direct ANDA substitution but face its own patent and clinical requirements

The practical loss-of-exclusivity date is therefore not necessarily the same as the nominal expiration date of the oldest listed patent.

What generic entry risks exist for JORNAY PM?

JORNAY PM presents a higher technical barrier than an immediate-release methylphenidate tablet, but it is not immune to generic competition.

Generic development risks

A generic developer must manage:

• Multiparticulate manufacturing.
• Drug-layering uniformity.
• Delayed-release reproducibility.
• Extended-release dissolution.
• Stability under long-term and accelerated conditions.
• Capsule-opening and sprinkle performance.
• Controlled-substance supply-chain requirements.
• Potentially complex pharmacokinetic studies.

The most difficult performance target is the combined lag-time and sustained-release profile. A product can match total exposure yet fail to match the timing of exposure.

Substitution risk

A therapeutically similar long-acting methylphenidate product may compete clinically without being pharmaceutically substitutable. Generic substitution is strongest when an ANDA is approved as therapeutically equivalent and receives an Orange Book therapeutic-equivalence code that supports substitution.

Competing products such as Concerta, Quillivant XR, Quillichew ER, Ritalin LA, and Daytrana use different delivery technologies and dosing schedules. They compete for the same ADHD population but do not all address the evening-dosing need in the same way.

How strong is the JORNAY PM patent estate?

The patent estate should be assessed across four layers:

1. Composition and dosage-form claims.
2. Delayed-release and extended-release bead architecture.
3. Method-of-use claims covering evening administration.
4. Manufacturing and coating-process claims.

Composition claims directed only to familiar excipients are usually less defensible than claims requiring a specific release profile or structural combination. Method-of-use claims may have commercial value but can be more vulnerable to design-around strategies, prescription behavior changes, or non-infringing labeling.

The estate is stronger when patents claim measurable technical results, such as a defined lag period, release percentages at specified time points, or pharmacokinetic parameters tied to the formulation. It is weaker when claims depend on broad excipient categories without narrow process or performance limitations.

What commercial opportunities exist for excipient suppliers?

Premium coating systems

Excipient companies can develop prequalified coating platforms using ethylcellulose, hypromellose, and citrate plasticizers. The commercial opportunity is a reproducible multiparticulate coating system with validated processing windows.

Potential products include:

• Ready-to-use aqueous polymer dispersions.
• Low-dusting coating premixes.
• Polymer systems optimized for pH-independent lag time.
• Coatings with improved resistance to cracking and abrasion.
• Solvent-reduced systems for controlled-substance manufacturing.

Functional sugar spheres

Suppliers can differentiate sugar spheres through tighter particle-size distributions, lower friability, improved surface uniformity, and controlled moisture. These attributes can reduce drug-layering variability and improve capsule-to-capsule dose uniformity.

Pediatric administration platforms

The ability to open JORNAY PM capsules and sprinkle the contents on applesauce creates an opportunity for excipient and device suppliers to develop pediatric multiparticulate platforms. Relevant attributes include:

• Low grittiness.
• Taste masking.
• Reduced adhesion to food.
• Stability after temporary mixing.
• No-chew robustness.
• Compatibility with soft foods.

A competing product that preserves evening dosing while improving palatability, portability, or swallowability could target patients who have difficulty with intact capsules.

Alternative capsule materials

Gelatin is the labeled shell material. Hypromellose capsules could provide a potential alternative for vegetarian, religious, or supply-chain reasons, although any change would require compatibility, dissolution, stability, and regulatory evaluation.

What lifecycle opportunities exist for JORNAY PM?

The main lifecycle opportunities are:

Opportunity	Strategic rationale
Lower-dose strengths	Supports titration and younger or sensitive patients
Pediatric sprinkle product	Reduces swallowing barriers
Longer stability dating	Improves pharmacy and wholesaler inventory
Sachet or unit-dose packaging	Helps school and caregiver administration
Alternative capsule shell	Broadens patient acceptability
New food-compatible presentation	Reduces administration variability
Abuse-deterrent design	Addresses stimulant misuse concerns
International formulation adaptation	Supports country-specific excipient and capsule requirements
Digital adherence support	Reinforces evening dosing and caregiver routines

A new formulation using the same active ingredient may require a 505(b)(2) application if it cannot qualify as an ANDA. The commercial case depends on improved administration, adherence, safety, or pharmacokinetic performance that is meaningful enough to justify a new development program.

What revenue exposure does JORNAY PM create?

Public company disclosures generally report broader product or ADHD portfolios rather than a fully separated JORNAY PM revenue line. Product-level revenue exposure should therefore be modeled using prescription volume, net price, payer coverage, patient assistance, and channel discounts rather than relying on headline company revenue.

The principal revenue risks are:

• Generic methylphenidate competition.
• Payer preference for lower-cost long-acting stimulants.
• Prior authorization requirements.
• Controlled-substance shortages.
• Reduced adherence caused by evening-dose complexity.
• Competing non-stimulant ADHD products.
• Product-specific manufacturing interruptions.

The principal revenue opportunities are patients who need early-morning symptom coverage, struggle with morning dosing, or require an alternative to conventional morning-administered methylphenidate.

Key Takeaways

• JORNAY PM's commercial differentiation comes from delayed-release and extended-release multiparticulate technology.
• Ethylcellulose, hypromellose, triethyl citrate, povidone, talc, and sugar spheres are central to process performance, but individual excipients are unlikely to provide meaningful standalone exclusivity.
• The main generic barrier is reproducing the combined lag-time and daytime release profile.
• The strongest lifecycle opportunities involve pediatric administration, sprinkle performance, capsule-shell alternatives, unit-dose packaging, and improved stability.
• FDA approval occurred in 2018 under NDA 211206 for ADHD patients age 6 years and older.
• Orange Book patent and exclusivity status must be evaluated from the current FDA record before making a launch or litigation decision.
• Revenue exposure depends on payer access, controlled-substance supply, generic timing, and the size of the patient population that benefits from evening dosing.

FAQs

Can JORNAY PM beads be crushed or chewed?

No. The capsule may be opened and sprinkled on applesauce, but the beads should not be crushed or chewed because doing so can disrupt the release-control coatings.[1]

Which excipient is most important for JORNAY PM's delayed release?

No single excipient determines the entire profile. The coating system, particularly the interaction among ethylcellulose, hypromellose, plasticizer, coating weight, and process conditions, controls performance.

Could a generic JORNAY PM use different excipients?

Yes. A generic product generally may use different inactive ingredients if it meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, safety, and labeling compatibility.

Is JORNAY PM interchangeable with Concerta?

Not automatically. The products use different delivery technologies and dosing schedules. Therapeutic interchangeability depends on the prescription, payer policy, pharmacist authority, and FDA therapeutic-equivalence status.

What is the most attractive excipient opportunity around JORNAY PM?

The strongest opportunity is a reproducible multiparticulate coating platform that improves lag-time control, scale-up, stability, and pediatric administration without compromising dissolution performance.

References

1. U.S. Food and Drug Administration. (2024). JORNAY PM prescribing information. Ironshore Pharmaceuticals, Inc. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/